T

he 21st Century Cures Act promises to ramp up funding for biomedical research while also loosening regulations governing drugs and medical devices. Supporters say it will speed up approval of new treatments, while critics are concerned that the safety and effectiveness may be compromised.

Before a panel discussion on the law hosted by the Harvard T.H. Chan School of Public Health and STAT, Ed Silverman, STAT senior writer and Pharmalot columnist, interviewed Aaron Kesselheim, associate professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, on Facebook live. The full Q&A video is here; the panel discussion will be available here.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X